Publications

Patient-reported treatment outcomes in ME/CFS a...

Key Tollovid Data: A total of 54 Long COVID patients reported taking Tollovid for at least 15 days participated in the study. 54% of patients reported feeling better, with 35%...

Tollovid as Rescue Agent for Paxlovid Rebound i...

Tollovid as Rescue Agent for Paxlovid Rebound in Acute Covid-19 Citation: A. Blumenthal and L. Morgentaler, Tollovid as Rescue Agent for Paxlovid Rebound in Acute Covid-19, ResearchGate (not peer-reviewed), 2022/08/01,...

Consequences of Microclot Pathophysiology Under...

Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation Citation: A. Blumenthal, and L. Morgentaler, Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation, ResearchGate (not...

The Value of 3CL Protease Inhibitor Supplementa...

The Value of 3CL Protease Inhibitor Supplementation in Long Haul Syndrome Patients? Citation: D. Arad, A. Blumenthal, E. Brownell, Z. Tasnim, M. March-Steinman, Y.  Jones, C. Herrold, The Value of...

3CL Protease Inhibitors in Chronic Long Covid A...

3CL Protease Inhibitors in Chronic Long Covid A Case Review: Effects of 3CL Protease Inhibitors Paxlovid® and Tollovid™ in a Patient with Chronic Long Covid Citation: A. Blumenthal and L....